Trial Profile
Predictive Biomarkers For Response To Nivolumab In Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Proof of concept; Therapeutic Use
- 28 Dec 2023 Results collecting samples from this study and investigating the association of immune-cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors' outcomes in patients with R/M HNSCC, published in the Annals of Oncology
- 13 Sep 2022 Results Evaluating the DNA damage response (DDR) network as predictor of nivolumab efficacy in head and neck squamous cell carcinoma presented at the 47th European Society for Medical Oncology Congress
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research